{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:45:39Z","timestamp":1792183539522,"version":"4.4.0"},"reference-count":33,"publisher":"Japanese Circulation Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1253\/circj.cj-10-1281","type":"journal-article","created":{"date-parts":[[2011,4,15]],"date-time":"2011-04-15T05:20:28Z","timestamp":1302844828000},"page":"1493-1505","source":"Crossref","is-referenced-by-count":103,"title":["Randomized Head-to-Head Comparison of Pitavastatin, Atorvastatin, and Rosuvastatin for Safety and Efficacy (Quantity and Quality of LDL)  - The PATROL Trial -"],"prefix":"10.1253","volume":"75","author":[{"given":"Keijiro","family":"Saku","sequence":"first","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"},{"name":"Department of Clinical and Applied Science, Graduate School of Medical Sciences, Fukuoka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Noda","sequence":"additional","affiliation":[{"name":"Department of Clinical and Applied Science, Graduate School of Medical Sciences, Fukuoka University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"The PATROL Trial Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69472-5"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60447-5"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000140261.58966.A4"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-09-0358"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847070-00003"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01688.x"},{"key":"7","unstructured":"7. Japanese Society of Hospital Pharmacists. Interview Form (Lipitor). http:\/\/products.pfizer.co.jp\/documents\/if\/lip\/lip01_if.htm (accessed December 20, 2010)."},{"key":"8","unstructured":"8. Japanese Society of Hospital Pharmacists. Interview Form (Crestor). http:\/\/med.astrazeneca.co.jp\/crestor\/ (accessed December 20, 2010)."},{"key":"9","unstructured":"9. Japanese Society of Hospital Pharmacists. Interview Form (Livalo). http:\/\/www.livalo.com\/sitemap.htm (accessed December 20, 2010)."},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.013"},{"key":"11","unstructured":"11. Japan Atherosclerosis Society (JAS). Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases. Tokyo: Japan Atherosclerosis Society, 2002."},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M800523-JLR200"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M500192-JLR200"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M600227-JLR200"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000134391.01498.b8"},{"key":"16","unstructured":"16. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Japanese version. http:\/\/www.jcog.jp\/doctor\/tool\/CTCAEv3J_070308.pdf#search='CTCAE (accessed December 22, 2010)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Danchin N, Chadarevian R, Gayet JL, Licour M, Valensi P. Compared with atorvastatin at the dose of 10mg per day rosuvastatin was more effective to reach an LDL goal of <1.00g\/l in high cardiovascular risk patients (ARIANE study). Ann Cardiol Angeiol (Paris) 2007; 56: 82-87.","DOI":"10.1016\/j.ancard.2007.01.003"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Leiter LA, Rosenson RS, Stein E, Reckless JP, Schulte KL, Schleman M, et al; POLARIS study investigators. Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Atherosclerosis 2007; 194: e154-e164.","DOI":"10.1016\/j.atherosclerosis.2006.12.001"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Am J Cardiol 2008; 102: 1654-1662.","DOI":"10.1016\/j.amjcard.2008.08.014"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yokote K, Bujo H, Hanaoka H, Shinomiya M, Mikami K, Miyashita Y, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008; 201: 345-352.","DOI":"10.1016\/j.atherosclerosis.2008.02.008"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: An 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther 2007; 29: 2365-2373.","DOI":"10.1016\/j.clinthera.2007.11.002"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-08-1051"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0269-5"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"issue":"5","key":"25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5551\/jat.E562","volume":"15","author":"YAMAKAWA TADASHI","year":"2008","ISSN":"https:\/\/id.crossref.org\/issn\/1340-3478","issn-type":"print"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Baker SK, Tarnopolsky MA. Statin-associated neuromyotoxicity. Timely Top Med Cardiovasc Dis 2005; 9: E26.","DOI":"10.1358\/dot.2005.41.4.908565"},{"key":"28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2007.01835.x"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.04.005"},{"issue":"6","key":"30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.5551\/jat.3764","volume":"17","author":"Kimura Kenjiro","year":"2010","ISSN":"https:\/\/id.crossref.org\/issn\/1340-3478","issn-type":"print"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P002816"},{"key":"32","unstructured":"32. Muravyov AV, Yakusevich VV, Surovaya L, Petrochenko A. The effect of simvastatin therapy on hemorheological profile in coronary heart disease (CHD) patients. Clin Hemorheol Microcirc 2004; 31: 251-256."},{"issue":"2","key":"33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1177\/147323000903700204","volume":"37","author":"NARA M","year":"2009","ISSN":"https:\/\/id.crossref.org\/issn\/0300-0605","issn-type":"print"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/circj\/75\/6\/75_CJ-10-1281\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T03:59:31Z","timestamp":1616644771000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/circj\/75\/6\/75_CJ-10-1281\/_article"}},"subtitle":["\u2013 The PATROL Trial \u2013"],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-10-1281","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}